MetaCap

Arcturus Therapeutics (ARCT) vs Pyxis Oncology (PYXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcturus Therapeutics (ARCT) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 19.0% versus a loss of 62.3%. Over five years, ARCT leads with a -81.3% price change compared with -85.9% for PYXS. Pyxis Oncology is the larger company by market cap ($216.5 million vs $214.7 million), about 1.0 times the size.

Arcturus Therapeutics converts more of its revenue into profit, with a net margin of -80.2% versus -574.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARCT+19.01%PYXS-62.29%
+183%+46%-90%
Nov 21, 20251 yearNov 20, 2026
ARCT-79.56%PYXS-85.99%
+35%-32%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARCT versus PYXS key metrics
MetricARCTPYXS
Share price$7.45$1.81
Market cap$214.73M$216.49M
1-day change-1.97%+7.74%
YTD return+21.53%+57.39%
1-year return+19.01%-62.29%
5-year return-81.32%-85.90%
EPS (TTM)$-3.10$-1.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$82.03M$13.86M
Revenue growth (YoY)-46.14%-14.17%
Net income (latest FY)$-65.78M$-79.62M
Gross margin—82.77%
Operating margin-92.96%-609.18%
Net margin-80.19%-574.55%
52-week high$17.96$5.55
52-week low$5.50$1.03
Distance from 52-week high-58.52%-67.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+218.12%+354.14%
Average volume851.45K1.06M
Shares outstanding28.82M119.61M
Employees10656
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARCT has outperformed PYXS by 81.3 percentage points over the past year.
  • Arcturus Therapeutics is more profitable, keeping -80.2 cents of every revenue dollar as net income versus -574.5 cents for Pyxis Oncology.
  • Pyxis Oncology grew revenue faster in its latest fiscal year (-14.17% vs -46.14%).

About Arcturus Therapeutics

ARCT stock →

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Pyxis Oncology

PYXS stock →

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

ARCT vs PYXS FAQ

Which is bigger, Arcturus Therapeutics or Pyxis Oncology?

Pyxis Oncology (PYXS) is larger, with a market capitalization of $216.49M compared with $214.73M for Arcturus Therapeutics (ARCT).

Which stock has performed better over the past year, ARCT or PYXS?

ARCT returned +19.01% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.

Are Arcturus Therapeutics and Pyxis Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons